Hi [[ session.user.profile.firstName ]]

Model-Based Strategy to Guide the Choice of Clinical Doses for ADC

Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving the therapeutic index, however the greatest challenge to date for developing ADCs is a narrow therapeutic window that often results in toxic effects occurring before an ADC reaches its maximally efficacious dose.

The PK/PD scientists at Pierre Fabre have developed the novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate (ADC W0101).

In this webinar, Dr Julie Desrivot Quénelle, the PKPD Project Lead at Pierre Fabre, will uncover the science behind the scenes and talk about model development characterizing:

1) The relationship between PK and tumor growth in xenograft mouse allowing to calculate the tumor-static concentrations (TSC), i.e. drug concentration leading to tumor volume stabilization. The comparison versus ADC PK parameters help to anticipate potential efficacious dosing regimen in human.

2) The ADC-induced toxicity in animal species and in patients. These models were further used to simulate potential patient outcomes, and to identify a safe dose range in clinical setting.

Presenter: Julie Desrivot Quénelle, PKPD Project Lead, Pierre Fabre
Host: Olivier Barberan, Director of Translational Medicine Solutions, Elsevier
Recorded Oct 27 2020 55 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre
Presentation preview: Model-Based Strategy to Guide the Choice of Clinical Doses for ADC

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • 「R&Dにおけるデジタルトランスフォーメーション~Scientific dataの活用~」 Aug 24 2021 4:15 am UTC 45 mins
    ライフサイエンス データ&アナリティクス ソリューションマネージャー 齋藤 美里
    - データ活用によるR&Dの加速
    - 現状と課題
    -フルテキストから得られる情報
    - グローバルにおける事例
  • Reaxys基礎編「なぜ反応・化合物検索ではノイズが多いのか?~ノイズを減らす構造描画とフィルター機能のノウハウ~」 Jul 15 2021 4:15 am UTC 45 mins
    カスタマーコンサルタント:今田 泰史
    Reaxysの初心者から中級者まで使えるMarvin JSでの構造描画テクニックについてご紹介。ノイズが出てしまう原因を解説し、いかにノイズを解消するかをデモンストレーション致します。また、検索結果を得た後に絞り込むためのフィルター機能の活用の仕方も併せて解説します。
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence May 25 2021 3:00 pm UTC 60 mins
    Jen Teske, Solution Sales Manager and Robert Niebergall, Customer Consultant
    • Information that can be retrieved through patent information provided by Reaxys
    • Patent update process
    • Use case: How to search patents using Biological Targets
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence Recorded: Apr 23 2021 44 mins
    Sejin Kim, Customer Consultant
    • Information that can be retrieved through patent information provided by Reaxys
    • Patent update process
    • Use case: How to search patents using Biological Targets
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence Recorded: Apr 16 2021 48 mins
    Dr Nilesh Rane, Solution Consultant
    • Information that can be retrieved through patent information provided by Reaxys
    • Patent update process
    • Use case: How to search patents using Biological Targets
  • Managing scientific literature for drug/device development and medical affairs Recorded: Mar 18 2021 36 mins
    Heather Desmarais, MLS (President, HJD Consulting LLC)
    Scientific literature is a critical component to virtually all aspects of a life science enterprise, including Medical Affairs, Pharmacovigilance, and R&D. However, the process of curating and sharing literature can lead to significant challenges in organizing content, facilitating collaboration, and copyright compliance.

    In many cases, reference management tools are used to manage the large amounts of literature that accumulate over time. While these tools are helpful for developing bibliographies, a more robust approach to managing literature should be considered in order to effectively collaborate and centralize information.

    Especially in the remote-working era, a proper method of literature management can benefit your entire organization. Learn how best practices in literature management can keep you and your colleagues up to date on new developments, support collaboration, enable workflows and more.

    Heather Desmarais is a knowledge and information management consultant, as well as the founder and principal of HJDesmarais Consulting LLC. Heather worked in academic and corporate information centers before launching her consulting business in 2015. She received her MLS from the State University of New York at Albany and is based in the Boston area.
  • Use Reaxys® Reaction Data to Create Chemistry Models Recorded: Feb 16 2021 50 mins
    Dr Michael Collingsworth and Dr Eric Gilbert
    It’s an exciting time for those working in predictive reaction chemistry – the different algorithms and approaches available, and the outcomes these are helping to generate. Having a scalable environment that enables model deployment back out to bench chemists is key.

    In this webinar Dr Michael Collingsworth (Elsevier, Reaction Workbench Product Owner) and Dr Eric Gilbert (Elsevier, Chemistry Consultant), will show the workbench environment, and demonstrate what it can enable, including efforts to create a model to predict reaction conditions.

    If you are interested in any of the following areas, the Entellect® Reaction Workbench can help you and your team.

    -Benchmark published models using Reaxys reaction data
    -Access harmonized Reaxys reaction data for predictive modeling
    -Creating your own predictive models
    -Having a scalable and simple way to deploy your work back to your bench chemists
  • Building smart and effective biomedical literature search strategies Recorded: Jan 26 2021 52 mins
    Jean Dominique Pierret and Caroline Muller
    Biomedical literature plays a key role in the development of effective and safe drugs. To avoid missing important insights it is critical your literature search is comprehensive. Additionally, to be efficient, you would like to avoid retrieving too many non-relevant articles.

    In this webinar, scientific information experts Dr. Jean Dominique Pierret (Elsevier) and Dr. Caroline Muller (Bioledge) will explain how to quickly and efficiently focus your search on what is essential to you. Wherever you work in drug development, this webinar is relevant for you.

    Using different databases and real-world examples, they will explain how to work with search operators to retrieve relevant literature.

    What will be discussed during this webinar will allow you to address topics such as:
    • Creating a selection of articles on bispecific antibodies for cancer treatment
    • Following trends in stents for heart infarction
    • Closely monitoring the safety concerns of a specific marketed drug
    • Review the latest literature about the specificity of a analytical test
    • And more
  • Property Searching in Reaxys and Related Chemistry Databases Recorded: Dec 10 2020 60 mins
    Prof. Damon. D. Ridley
    How do we find reliable spectroscopic, physico-chemical or biochemical properties of chemical substances quickly?
    Prof. Damon Ridley will walk us through the exciting world of chemical compound property searching. He is illustrating what databases are available, most reliable and comprehensive enough to serve your scientific needs.
  • The Role of Scientific Literature in Pharmacovigilance: Challenges, Solutions & Recorded: Dec 10 2020 138 mins
    Dr Avinash Kakade, Dr Manoj Swaminathan, Dr Jean-Dominique, Dr Dhanraj,Dr Kabil Kalathingal, Mr Prashant Joshi, Ms Michelle
    This 2-hour webinar brings together leading individuals and thought leaders from Pharmacovigilance sharing best practices and strategies on how drug safety professionals can overcome the research challenges in this Covid-19 environment.
  • Text Mining to Identify Emerging Trends in Pancreatic Cancer Literature Recorded: Nov 19 2020 33 mins
    Dr. Eric GIlbert, Professional Services
    Text mining is one way to analyze emerging trends in research literature. Here we show how Elsevier’s text mining tool can be used to identify emerging trends using pancreatic cancer as an example. Firstly, trending taxonomy terms are identified by fitting a regression line to the normalized quarterly counts of publications in which the term is found. Then regression parameters are used to filter for terms that have the greatest fold change in publication counts over the time period. The workflow describing the capturing of trending terms will be described in detail. Several captured terms will be highlighted to demonstrate the insights that can be gained in this type of analysis.

    About the speaker:

    Dr. Eric Gilbert is an accomplished medicinal chemistry research scientist with over 15 years of experience in drug discovery at Pfizer, Schering-Plough, and Merck. He is the author and coauthor of 16 publications and an inventor for 22 issued US patents. Eric possesses a unique combination of synthesis and drug discovery experience along with an extensive data science background.
  • How scholarly literature can support Medical Science Liaisons Recorded: Nov 10 2020 43 mins
    Dr. Nadège Krebs
    Medical Affairs specialists facilitate the flow of unbiased information from science to pharma as medical science liaisons. This efficient exchange between the medical community and the pharmaceutical industry is of paramount importance. It helps pharmaceutical companies reduce healthcare costs and better meet consumer expectations. Medical information specialists have become the ‘go-to partner’ within pharma organizations.

    Comprehensive biomedical literature plays a critical role in synthesizing important literature on on drug safety, pharmacoepidemiology, key opinion leaders (KOLs) and much more.In this webinar, you will learn how you can use Embase to extract and synthesize the most relevant information from a sea of data. Embase is the world’s most comprehensive biomedical research and literature database.

    Dr. Nadège Krebs will discuss how to:
    • Find the latest reports on the burden of a disease or its epidemiology
    • Identify the pharma KOLs to build partnerships
    • Gather literature on the latest clinical trials for colleagues and/or patients

    Discover why 8 international organizations and regulatory authorities recommend Embase.

    About the speaker: Nadège is an Embase expert and a solution consultant for corporate companies across Europe. She has helped different stakeholders to answer questions ranging from disease burden to medical devices comparisons to drug pharmacovigilance using Embase.
  • 特定ターゲットに対して活性を示す化合物の同定 ~Reaxys/Reaxys Medicinal Chemistryを用いたSAR解析~ Recorded: Nov 5 2020 39 mins
    鈴木 直子
    生物活性データを保持するReaxys Medicinal ChemistryをReaxys上で利用し、特定のターゲットへ高い親和性をもつコア骨格を保持した化合物を同定する方法を紹介する。
    また、それらが特許範囲に含まれるか、またどうやって合成するかについての検討方法についても紹介する。
  • Optimizing personalized drug dosing for patients with drug-specific PK models Recorded: Oct 29 2020 56 mins
    Olivier Barberan/Aurélie Lereclus
    Fully understanding the Pharmacokinetic properties of a drug is crucial for safe administration of drugs. Too high levels of exposure to a drug can cause severe adverse events whereas a too low exposure can result in the drug not being effective. Differences between patients such as age, gender, kidney status, genotype, smoker, organ impairment or other individual characteristics can significantly influence the pharmacokinetics of a drug.

    In clinical research, Pharmacokinetic properties are often determined on homogenous population of healthy volunteers. Based on these data, there is often only one recommended dose for all patients (for example 200mg, twice a day). This can result in unexpected dangerous underexposure or overexposure when administering drugs in a highly heterogenous real-world populations. Therefore, adjusting drug dosing to the characteristics of individual patients can significantly reduce adverse events and improve clinical outcomes.

    Join us for this partner webinar where Elsevier and ExactCure will discuss:

    *The importance of modelling PK behavior of drugs based on patient characteristics to adjust dosing at individual patient level
    *The progress in developing phenotype and genotypic high quality dynamic Pharmacokinetic models
    *The need for high quality data to build Pharmacokinetic data models
    *How Elsevier and ExactCure are working together to build personalized drug-specific exposure models that allow the prediction of pharmacokinetic properties
  • Model-Based Strategy to Guide the Choice of Clinical Doses for ADC Recorded: Oct 27 2020 55 mins
    Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre
    Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving the therapeutic index, however the greatest challenge to date for developing ADCs is a narrow therapeutic window that often results in toxic effects occurring before an ADC reaches its maximally efficacious dose.

    The PK/PD scientists at Pierre Fabre have developed the novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate (ADC W0101).

    In this webinar, Dr Julie Desrivot Quénelle, the PKPD Project Lead at Pierre Fabre, will uncover the science behind the scenes and talk about model development characterizing:

    1) The relationship between PK and tumor growth in xenograft mouse allowing to calculate the tumor-static concentrations (TSC), i.e. drug concentration leading to tumor volume stabilization. The comparison versus ADC PK parameters help to anticipate potential efficacious dosing regimen in human.

    2) The ADC-induced toxicity in animal species and in patients. These models were further used to simulate potential patient outcomes, and to identify a safe dose range in clinical setting.

    Presenter: Julie Desrivot Quénelle, PKPD Project Lead, Pierre Fabre
    Host: Olivier Barberan, Director of Translational Medicine Solutions, Elsevier
  • DNA-encoded libraries in drug discovery Recorded: Oct 14 2020 78 mins
    Dr. Alex Satz; Dr. Andreas Brunschweiger
    DNA-Encoded library (DEL) screening is now commonly used in the pharmaceutical industry to find novel chemical matter that modulates protein targets of interest. A DEL is a mixture of millions of drug-like small-molecules, where each molecule is conjugated to a DNA-oligomer that encodes its chemical structure. The composition of a DEL mixture can be readily interrogated before and after interaction with a protein target by Next Generation Sequencing, and small-molecules that selectively bind the target identified.

    We’re excited to invite you to a webinar on this topic that Dr. Alex Satz, senior director of DEL strategy and operations at WuXi AppTec, will talk about the current learnings in DEL design, synthesis, and screening, followed by a presentation from Dr. Andreas Brunschweiger of TU Dortmund University on research demonstrating the role of cheminformatics and DNA-encoded chemistry in compound identification.

    About speakers:
    Alex Satz has 15+ years experience building DNA encoded library (DEL) platforms, and is currently the senior director of DEL strategy and operations at WuXi AppTec. Prior to WuXi AppTec, Alex led the Roche DEL platform in Basel Switzerland, and helped to develop the first industrial-scale DEL platform at Praecis Pharmaceuticals and GlaxoSmithKline.
    Andreas Brunschweiger is a group leader at the Departmend of Chemistry and Chemical Biology of TU Dortmund University. His current research interests include the development of computer-assisted tools for DNA-endoced library design, synthesis and encoding strategies that expand the chemical space of DNA-encoded libraries, and asssays for hit identification.
  • Reaxys逆合成予測ツールのご紹介 Recorded: Oct 8 2020 45 mins
    鈴木 直子
    低分子化合物の一連の合成反応のプランニング作成を助けるReaxysの新しい
    ソリューションとなる逆合成予測ツールをご紹介します。
    2018年にNature誌に発表されたM.H.S. SeglerとM. Waller(現Pending.AI)の
    画期的な研究に基づいて開発されたこの新しいソリューションは、最先端の
    ディープラーニング技術とReaxysの高品質な反応データを活用しています。
    このディープラーニング技術により、AIが化学反応を自己学習し、それに
    基いた逆合成予測によりアイデア創出等にご活用ください。
  • Using machine learning to extract chemical information from patents Recorded: Oct 7 2020 57 mins
    Saber Akhondi, Principle NLP Scientist, Elsevier
    In commercial research and development projects, public disclosure of new chemical compounds and reactions often takes place in patents. Only a small proportion of these compounds are published in journals, usually a few years after the patent. Patent authorities make available the patents but do not provide systematic continuous chemical annotations. Different text-mining approaches exist to extract chemical information from patents but less attention has been given to relevancy of a compound in a patent. Relevancy of a compound to a patent is based on the patent’s context. A relevant compound plays a major role within a patent. Identification of relevant compounds reduces the size of the extracted data and improves the usefulness of patent resources (e.g. supports identifying the main compounds). Annotators of databases like Reaxys only annotate relevant compounds.
    Using the advanced technologies in Artificial intelligence (AI), Machine learning (ML) and Natural language processing (NLP), we have developed models to overcome these limitations. Through shared evaluation campaign we have also invited academic and industrial teams to further develop, improve and contribute to the domain of patent information extraction.

    The webinar will discuss:
    - The challenges of patent mining in the chemical domain
    - Chemical information extraction. From relevant document to relevant section to relevant information.
    - How to create a quality training set for machine learning in Chemistry
    - The ChEMU shared task for name entity and event extraction

    About speaker:

    Saber Akhondi obtained his MSc degree in Bioinformatics and Systems Biology from Chalmers University of Technology, Sweden. In 2011 he started as a PhD student within the biosemantics group in Erasmus Medical Center Rotterdam. He currently works at Elsevier as a Principle NLP Scientist where he applies NLP and machine learning techniques to extract information useful for large commercial and research communities.
  • Early Chemical Development on BMS-986095 for Hepatitis C Virus Recorded: Sep 23 2020 54 mins
    Changxia Yuan,Senior Research Investigator, Bristol Myers Squibb and Scott Newman, Customer Consultant, Elsevier
    Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. Chemical development of the synthetic/production process impact go/no go decisions of lead molecules. These include
    •Developing or inventing new routes for important process intermediates at scale
    •Optimizing reaction conditions for multiple routes based on novel reactants
    •Yield considerations at each step
    Each of these will be examined using a small molecule Hepatitis C nucleotide polymerase inhibitor that has been developed by BMS as a model.
  • COVID-19 search strategies in PharmaPendium: Focus on DMPK and DDIs Recorded: Sep 17 2020 47 mins
    Marnix Wieffer
    Many already approved drugs are currently being tested (repurposed) for prevention and treatment of COVID-19 infections and symptoms. To maximize repurposing and treatments success, you need to be fully informed on all regulatory DMPK, efficacy and drug safety data available on EMA and FDA approved drugs.

    Elsevier’s PharmaPendium provides access to full text searchable FDA/EMA drug approval Documents, manually extracted data, expert taxonomies and prediction tools. Thereby it is ideally positioned to support COVID-19 repurposing and treatments effort.

    In this webinar, PharmaPendium product manager Thomas Vargues and senior marketing manager drug safety Marnix Wieffer will show various PharmaPendium search strategies that are currently being used by pharmaceutical and healthcare customers.

    For this webinar they will focus on DMPK and DDI risk prediction workflows. For example:
    1.How does patient complications influence therapeutic PK profile and exposure?
    2. What DDIs can I expect now I am creating uncommon drug combinations?
    3.How to use Pharmacokinetic data to model exposure in COVID-19 patients?

    Getting answers to these critical questions can support drug repurposing efforts and reduce risk for patients.
Webinars supporting your innovation, compliance needs, and safety
Realize the potential of data-driven drug discovery and development with solutions that help you increase research efficiency and ensure a thriving R&D pipeline.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Model-Based Strategy to Guide the Choice of Clinical Doses for ADC
  • Live at: Oct 27 2020 3:00 pm
  • Presented by: Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre
  • From:
Your email has been sent.
or close